Ariadne Bio launches a clinical trial in late 2026 to tackle apathy in Parkinson's using a novel serotonin therapy

Ariadne Bio has launched as a dedicated biotechnology company to take on one of the most frustrating aspects of living with Parkinson's: the loss of motivation, clinically known as apathy. Supported by funding from The Michael J. Fox Foundation, the team plans to start human trials later this year with an experimental compound called AB300. Apathy affects roughly four in ten people with the condition, yet there is currently no approved medicine to treat it. Families and carers often mention that this emotional flattening causes even more daily distress than physical stiffness or tremor. It is not simply being lazy or feeling down. Instead, the brain's internal spark plug misfires, making even the smallest goal seem impossible to begin. While standard antidepressants such as SSRIs can lift low mood, they often make apathy worse by blunting feelings even further. Scientists previously assumed that dopamine loss alone explained this drop in drive. However, brain imaging in people with the condition revealed that apathy actually tracks closely with changes in serotonin networks. Ariadne Bio is taking advantage of that insight. Their lead drug, AB300, selectively stimulates a specific brain switch called the serotonin 2A receptor. Although related chemical families are famous for psychedelic effects, this compound is engineered to be entirely non hallucinogenic. Crucially, it does not touch dopamine receptors at all. In early laboratory tests of dopamine shortage, the molecule boosted goal directed effort by eighty nine percent, with the strongest turnaround seen in the subjects who had lost the most motivation. The upcoming Phase 1b trial will run across specialist clinical centres in Austria and Israel. If the drug performs as well in people as it did in early tests, it could offer the first true medical option to help switch motivation back on.